¹⁷⁷Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.

The Bliss independence model indicated significant synergism in combining 350 MBq/kg 177 Lu-lilotomab with rituximab ( P < 0.05 for tumor volumes measured 17 and 20 days after treatment), whereas the combination of 150 MBq/kg 177 Lu-lilotomab and rituximab did not reach statistical significance for any time point ( Fig. 3A ).

also in 111,027 other papers